Veraxa Biotech files first BiTAC-related patent applications for cancer therapy platforms - VRXA News | RalliesVeraxa Biotech files first BiTAC-related patent applications for cancer therapy platforms
V
VRXA• First BiTAC-related patent applications filed
- Veraxa Biotech filed its first BiTAC-related patent applications in H1 2026 covering composition of matter for its BiTAC-TCE and BiTAC-ADC platforms.
- Additional applications cover a proprietary payload platform, click chemistry, and conjugation technology used in its programs.
- Portfolio totals more than 50 granted owned or exclusively licensed patents across 26 families in 14 countries.
- Pending applications, once granted, are expected to extend protection for core technologies through at least 2047.
VASO
•
